The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability

ACS Chemical Neuroscience

Volumn 4, Issue 2, 2013, Pages 214-224

  Lin, Ann P ^a   Ko, Mei Chuan ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

abuse liability; analgesia; macaques; Nociceptin orphanin FQ; NOP receptors; spinal cord

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ALFENTANIL; ANALGESIC AGENT; FENTANYL; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALTREXONE; NOCICEPTIN; NOCICEPTIN RECEPTOR; OPIATE RECEPTOR; RO 646198; SCH 221510; SR 16435; SR 16835; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIA; ANTINOCICEPTION; COMPETITIVE INHIBITION; DOSE RESPONSE; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SPINAL ANESTHESIA; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; AZABICYCLO COMPOUNDS; IMIDAZOLES; MACACA; PAIN; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SPIRO COMPOUNDS; SUBSTANCE-RELATED DISORDERS;

EID: 84874057237     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn300124f     Document Type: Review

References (103)

1. Cicero, T. J., Dart, R. C., Inciardi, J. A., Woody, G. E., Schnoll, S., and Munoz, A. (2007)) The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS) Pain Med. 8, 157-170
2. Sullivan, M. D., Von Korff, M., Banta-Green, C., Merrill, J. O., and Saunders, K. (2010) Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain Pain 149, 345-353
3. Sehgal, N., Manchikanti, L., and Smith, H. S. (2012) Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse Pain Physician 15, ES67-ES92
4. Boscarino, J. A., Rukstalis, M., Hoffman, S. N., Han, J. J., Erlich, P. M., Gerhard, G. S., and Stewart, W. F. (2010) Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system Addiction 105, 1776-1782
5. Nelson, L. S. and Perrone, J. P. (2012) Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS) JAMA, J. Am. Med. Assoc. 308, 457-458
6. Hansen, R. N., Oster, G., Edelsburg, J., Woody, G. E., and Sullivan, S. D. (2011) Economic costs of nonmedical use of prescription opioids Clin. J. Pain 27, 194-202
7. Licup, N. and Baumrucker, S. J. (2010) Methylnaltrexone: treatment for opioid-induced constipation Am. J. Hosp. Palliative Med. 28, 59-61
8. Camilleri, M. (2011) Opioid-induced constipation: challenges and therapeutic opportunities Am. J. Gastroenterol. 106, 835-842
9. Hjalte, F., Berggren, A., Bergendahl, H., and Hjortsberg, C. (2010) The direct and indirect costs of opioid-induced constipation J. Pain Symptom Manage. 40, 696-703
10. DeBalli, P. and Breen., T. W. (2003) Intrathecal opioids for combined spinal-epidural analgesia during labour CNS Drugs 17, 889-904
11. Macintyre, P. E., Loadsman, J. A., and Scott, D. A. (2011) Opioids, ventilation and acute pain management Anaesth. Intensive Care 39, 545-558
12. Cousins, M. J. and Mather, L. E. (1984) Intrathecal and epidural administration of opioids Anesthesiology 61, 276-310
13. Ganesh, A. and Maxwell, L. G. (2007) Pathophysiology and management of opioid-induced pruritus Drugs 67, 2323-2333
14. Szarvas, S., Harmon, D., and Murphy, D. (2003) Neuraxial opioid-induced pruritus: a review J. Clin. Anesth. 15, 234-239
15. Corbett, A. D., Henderson, G., McKnight, A. T., and Paterson, S. J. (2006) 75 years of opioid research: the exciting but vain quest for the Holy Grail Br. J. Pharmacol. 147, S153-S162
16. Rang, H. P., Dale, M. M., and Ritter, J. M. (2007) Rang and Dale's Pharmacology (6 th Ed.), Analgesic Drugs, pp 562-584, Edinburgh, Churchill Livingstone.
17. Dykstra, L. A., Gmerek, D. E., Winger, G., and Woods, J. H. (1987) Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects J. Pharmacol. Exp. Ther. 242, 413-420
18. Butelman, E. R., Harris, T. J., and Kreek, M. J. (1999) Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys Psychopharmacology 147, 73-80
19. Ko, M. C. H., Johnson, M. D., Butelman, E. R., Willmont, K. J., Mosberg, H. I., and Woods, J. H. (1999b) Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys J. Pharmacol. Exp. Ther. 291, 1113-1120
20. Nagase, H. and Fujii, H. (2011) Opioids in preclinical and clinical trials Top. Curr. Chem. 299, 29-62
21. Dykstra, L. A., Schoenbaum, G. M., Yarbrough, J., McNutt, R., and Chang, K. J. (1993) A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration J. Pharmacol. Exp. Ther. 267, 857-882
22. Negus, S. S., Butelman, E. R., Chang, K. J., DeCosta, B., Winger, G., and Woods, J. H. (1994) Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys J. Pharmacol. Exp. Ther. 270, 1025-1034
23. Negus, S. S., Gatch, M. B., Mello, N. K., Zhang, X., and Rice, K. (1998) Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys J. Pharmacol. Exp. Ther. 286, 362-375
24. Nozaki, C., Le Bourdonnec, B., Reiss, D., Windh, R. T., Little, P. J., Dolle, R. E., Kieffer, B. L., and Gaveriaux-Ruff, C. (2012) Delta-opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization J. Pharmacol. Exp. Ther. 342, 799-807
25. Neilan, C. L., Husbands, S. M., Breeden, S., Ko, M. C., Aceto, M. D., Lewis, J. W., Woods, J. H., and Traynor, J. R. (2004) Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting μ-opioid receptor agonist Eur. J. Pharmacol. 499, 107-116
26. Raehal, K. M., Lowery, J. J., Bhamidipati, C. M., Paolino, R. M., Blair, J. R., Wang, D., Sadee, W., and Bilsky, E. J. (2005) In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice J. Pharmacol. Exp. Ther. 313, 1150-1162
27. Ko, M. C. H., Divin, M. F., Lee, H., Woods, J. H., and Traynor, J. R. (2006a) Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey J. Pharmacol. Exp. Ther. 316, 772-779
28. Paul, D., Levison, J. A., Howard, D. H., Pick, C. G., Hahn, E. F., and Pasternak, G. W. (1990) Naloxone benzoylhydrazone (NalBzoH) analgesia J. Pharmacol. Exp. Ther. 255, 769-774
29. France, C. P. and Woods, J. H. (1992) Naloxone benzoylhydrazone is a mu-selective opioid antagonist without kappa-agonist effects in rhesus monkeys Behav. Pharmacol. 3, 133-141
30. Kamei, J. and Nagase, H. (2001) Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice Eur. J. Pharmacol. 418, 141-145
31. Ko, M. C. H., Lee, H., Song, M. S., Sobczyk-Kojiro, K., Mosberg, H. I., Kishioka, S., Woods, J. H., and Naughton, N. N. (2003a) Activation of kappa Opioid Receptors Inhibits Pruritus Evoked by Subcutaneous or Intrathecal Administration of Morphine in Monkeys J. Pharmacol. Exp. Ther. 305, 173-179
32. Lee, H., Naughton, N. N., Woods, J. H., and Ko, M. C. (2007) Effects of butorphanol on morphine-induced itch and analgesia in primates Anesthesiology 107, 478-485
33. Liu-Chen, L. Y. (2004) Agonist-induced regulation and trafficking of kappa-opioid receptors Life Sci. 75, 511-536
34. Wild, K. D., McCormick, J., Bilsky, E. J., Vanderah, T., McNutt, R. W., Chang, K. J., and Porreca, F. (1993) Antinociceptive actions of BW373U86 in the mouse J. Pharmacol. Exp. Ther. 267, 858-865
35. Ko, M. C. H., Lee, H., Harrison, C., Clark, M. J., Song, H. F., Naughton, N. N., Woods, J. H., and Traynor, J. R. (2003b) Studies of μ-, κ-, and δ-opioid receptor density and G protein activation in the cortex and thalamus of monkeys J. Pharmacol. Exp. Ther. 306, 179-186
36. Ko, M. C. H., Lee, H., Traynor, J. R., Woods, J. H., and Naughton, N. N. (2003c) Differential antinociceptive effects of intrathecally administered opioid agonists selective for mu, kappa, and delta opioid receptors in monkeys Drug Alcohol Depend. 69 (Suppl) 87
37. 1 receptor antagonist ELN441958 J. Pharmacol. Exp. Ther. 322, 619-630
38. Leffler, A., Ahlstedt, I., Engberg, S., Svensson, A., Billger, M., Oberg, L., Bjursell, M. K., Lindstrom, E., and von Mentzer, B. (2009) Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3 Biochem. Pharmacol. 77, 1522-1530
39. Bianchi, B. R., Zhang, X. F., Reilly, R. M., Kym, P. R., Yao, B. B., and Chen, J. (2012) Species comparison and pharmacological characterization of human, monkey, rat, and mouse TRPA1 channels J. Pharmacol. Exp. Ther. 341, 360-368
40. LaMotte, R. H. and Campbell, J. N. (1978) Comparison of responses of warm and nociceptive C-fiber afferents in monkey with human judgments of thermal pain J. Neurophysiol. 41, 509-528
41. Rozsa, A. J., Molinari, H. H., Greenspan, J. D., and Kenshalo, D. R., Sr. (1985) The primate as a model for the human temperature-sensing system: 1. Adapting temperature and intensity of thermal stimuli Somatosens. Res. 2, 303-314
42. Mansour, A., Khachaturian, H., Lewis, M. E., Akil, H., and Watson, S. J. (1988) Anatomy of CNS opioid receptors Trends Neurosci. 11, 308-314
43. Kenshalo, D. R., Jr., Anton, F., and Dubner, R. (1989) The detection and perceived intensity of noxious thermal stimuli in monkey and in human J. Neurophysiol. 62, 429-436
44. Ko, M. C. H. and Naughton, N. N. (2000) An experimental itch model in monkeys: Characterization of intrathecal morphine-induced scratching and antinociception Anesthesiology 92, 795-805
45. Ko, M. C. and Husbands, S. M. (2009) Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates J. Pharmacol. Exp. Ther. 328, 193-200
46. Lee, H., Naughton, N. N., Woods, J. H., and Ko, M. C. H. (2003) Characterization of scratching responses in rats following centrally administered morphine or bombesin Behav. Pharmacol. 14, 501-508
47. Bailey, P. L., Rhondeau, S., Schafer, P. G., Lu, J. K., Timmins, B. S., Foster, W., Pace, N. L., and Stanley, T. H. (1993) Dose-response pharmacology of intrathecal morphine in human volunteers Anesthesiology 79, 49-59
48. Palmer, C. M., Emerson, S., Volgoropolous, D., and Alves, D. (1999) Dose-response relationship of intrathecal morphine for postcesarean analgesia Anesthesiology 90, 437-444
49. Kuhar, M. J., Pert, C. B., and Snyder, S. H. (1973) Regional distribution of opiate receptor binding in monkey and human brain Nature (London, U.K.) 245, 447-450
50. Zacny, J. P., Conley, K., and Galinkin, J. (1997) Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers J. Pharmacol. Exp. Ther. 282, 1187-1197
51. Pergolizzi, J., Aloisi, A. M., Dahan, A., Filitz, J., Langford, R., Mercadante, S., Morlion, B., Raffa, R. B., and Sabatowski, R. (2010) Current knowledge of buprenorphine and its unique pharmacological profile Pain Pract. 10, 428-450
52. Cremeans, C. M., Gruley, E., Kyle, D. J., and Ko, M. C. (2012) Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates J. Pharmacol. Exp. Ther. 343, 72-81
53. Mollereau, C., Parmentier, M., Mailleux, P., Butour, J. L., Moisand, C., Chalon, P., Caput, D., Vassart, G., and Meunier, J. C. (1994) ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization FEBS Lett. 341, 33-38
54. Foord, S. M., Bonner, T. I., Neubig, R. R., Rosser, E. M., Pin, J.-P., Davenport, A. P., Spedding, M., and Harmar, A. J. (2005) International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List Pharmacol. Rev. 57, 279-288
55. Henderson, G. and McKnight, A. T. (1997) The orphan opioid receptor and its endogenous ligand-nociceptin/orphanin FQ Trends Pharmacol. Sci. 18, 293-300
56. Calo, G., Guerrini, R., Rizzi, A., Salvadori, S., and Regoli, D. (2000) Pharmacology of nociceptin and its receptor: a novel therapeutic target Br. J. Pharmacol. 129, 1261-1283
57. Civelli, O., Nothacker, H. P., and Reinscheid, R. (1998) Reverse physiology: discovery of the novel neuropeptide, orphanin FQ/nociceptin Crit. Rev. Neurobiol. 12, 163-176
58. Mogil, J. S. and Pasternak, G. W. (2001) The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family Pharmacol. Rev. 53, 381-415
59. Lambert, D. G. (2008) The nociception/orphanin FQ receptor: a target with broad therapeutic potential Nat. Rev. Drug Discovery 8, 694-710
60. Largent-Milnes, T. M. and Vanderah, T. W. (2010) Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin. Ther. Pat. 20, 291-305
61. Meunier, J. C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., Butour, J. L., Guillemot, J. C., Ferrara, P., Monsarrat, B., Mazarguil, H., Vassart, G., parmentier, M., and Constantin, J. (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor Nature 377, 532-535
62. Reinscheid, R. K., Nothacker, H. P., Bourson, A., Ardati, A., Henningsen, R. A., Bunzow, J. R., Grandy, D. K., Langen, H., Monsma, F. J., Jr., and Civelli, O. (1995) Orphanin FQ: A neuropeptide that activates an opioidlike G protein-coupled receptor Science 270, 792-794
63. Connor, M., Yeo, A., and Henderson, G. (1996) The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH-SY5Y human neuroblastoma cell line Br. J. Pharmacol. 118, 205-207
64. Vaughan, C. W. and Christie, M. J. (1996) Increase by the ORL1 receptor (opioid receptor-like-1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones Br. J. Pharmacol. 117, 1609-1611
65. Giuliani, S. and Maggi, C. A. (1996) Inhibition of tachykinin release from peripheral endings of sensory nerves by nociceptin, a novel opioid peptide Br. J. Pharmacol. 118, 1567-1569
66. Helyes, Z., Nemeth, J., Pinter, E., and Szolcsanyi, J. (1997) Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals Br. J. Pharmacol. 121, 613-615
67. Xu, X. J., Hao, J. X., and Wiesenfeld-Hallin, Z. (1996) Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat NeuroReport 7, 2092-2094
68. Erb, K., Liebel, J. T., Tegeder, I., Zeilhofer, H. U., Brune, K., and Geisslinger, G. (1997) Spinally delivered nociceptin/orphanin FQ reduces flinching behaviour in the rat formalin test NeuroReport 8, 1967-1970
69. Yamamoto, T., Nozaki-Taguchi, N., and Kimura, S. (1997) Analgesic effect of intrathecally administered nociceptin, an opioid receptor-like1 receptor agonist, in the rat formalin test Neuroscience 81, 249-254
70. Sakurada, T., Katsuyama, S., Sakurada, S., Inoue, M., Tan-No, K., Kisara, K., Sakurada, C., Ueda, H., and Sasaki, J. (1999) Nociceptin-induced scratching, biting and licking in mice: involvement of spinal NK1 receptors Br. J. Pharmacol. 127, 1712-1718
71. Ko, M. C. H., Wei, H., Woods, J. H., and Kennedy, R. T. (2006b) Effects of intrathecally administered nociception/orphanin FQ in monkeys: behavioral and mass spectrometric studies J. Pharmacol. Exp. Ther. 318, 1257-1264
72. Ko, M. C. H., Song, M. S., Edwards, T., Lee, H., and Naughton, N. N. (2004) The role of central mu opioid receptors in opioid-induced itch in primates J. Pharmacol. Exp. Ther. 310, 169-176
73. Ko, M. C. and Naughton, N. N. (2009) Antinociceptive effects of nociception/orphanin FQ administered intrathecally in monkeys J. Pain 10, 509-516
74. Arduin, M., Spagnolo, B., Calo, G., Guerrini, R., Carra, G., Fischetti, C., Trapella, C., Marzola, E., McDonald, J., Lambert, D. G., Regoli, D., and Salvadori, S. (2007) Synthesis and biological activity of nociceptin/orphanin FQ analogues subsituted in position 7 or 11 with Cα,α-dialkylated amino acids Bioorg. Med. Chem. 15, 4434-43
75. Rizzi, A., Spagnolo, B., Wainford, R. D., Fischetti, C., Guerrini, R., Marzola, G., Baldisserotto, A., Salvadori, S., Regoli, D., Kapusta, D. R., and Calo, G. (2007) In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor Peptides 28, 1240-51
76. Calo', G., Rizzi, A., Cifani, C., Micioni, Di Bonaventura, M. V., Regoli, D., Massi, M., Salvadori, S., Lambert, D. G., and Guerrini, R. (2011) UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor CNS Neurosci. Ther. 17, 178-98
77. Hu, E., Calo, G., Guerrini, R., and Ko, M. C. (2010) Long-lasting antinociceptive spinal effects in primates of the novel nociception/orphanin FQ receptor agonist UFP-112 Pain 148, 107-113
78. Jenck, F., Wichmann, J., Dautzenberg, F. M., Moreau, J. L., Ouagazzal, A. M., Martin, J. R., Lundstrom, K., Cesura, A. M., Poli, S. M., Roever, S., Kolczewski, S., Adam, G., and Kilpatrick, G. (2000) A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat Proc. Natl. Acad. Sci. U.S.A. 97, 4938-4943
79. Le Pen, G., Wichmann, J., Moreau, J. C., and Jenck, F. (2002) The orphanin receptor agonist Ro 64-6198 does not induce place conditioning in rats NeuroReport 13, 451-454
80. Kuzmin, A., Sandin, J., Terenius, L., and Ogren, S. O. (2003) Acquisition, Expression, and Reinstatement of Ethanol-Induced Conditioned Place Preference in Mice: Effects of Opioid Receptor-Like 1 Receptor Agonists and Naloxone J. Pharmacol. Exp. Ther. 304, 310-318
81. Dautzenberg, F. M., Wichmann, J., Higelin, J., Py-Lang, G., Kratzeisen, C., Malherbe, P., Kilpatrick, G. J., and Jenck, F. (2001) Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo J. Pharmacol. Exp. Ther 298, 812-819
82. Reiss, D., Wichmann, J., Tekeshima, H., Kieffer, B. L., and Ouagazzal, A. M. (2008) Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro 64-6198, on reactivity to acute pain in mice: Comparison to morphine Eur. J. Pharmacol. 579, 141-148
83. Ko, M. C. (2004) Antinociceptive effects of ORL1 agonists in monkeys FASEB J. 18, A961
84. Ko, M. C., Woods, J. H., Fantegrossi, W. E., Galuska, C. M., Wichmann, J., and Prinssen, E. P. (2009) Behavioral effects of a synthetic agonist selective for nociception/orphanin FQ peptide receptors in monkeys Neuropsychopharmacology 34, 2088-2096
85. Szallasi, A., Cortright, D. N., Blum, C. A., and Eid, S. R. (2007) The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof of concept Nat. Rev. Drug Discovery 6, 357-372
86. Park, K. M., Max, M. B., Robinovitz, E., Gracely, R. H., and Bennett, G. J. (1995) Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects Pain 63, 163-172
87. Eisenach, J. C., Hood, D. D., Curry, R., and Tong, C. (1997) Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans Anesthesiology 86, 1279-1287
88. Butelman, E. R., Harris, T. J., and Kreek, M. J. (2004) Antiallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates J. Pharmacol. Exp. Ther. 311, 155-163
89. Varty, G. B., Lu, S. X., Morgan, C. A., Cohen-Williams, M. E., Hodgson, R. A., Smith-Torhan, A., Zhang, H., Fawzi, A. B., Graziano, M. P., Ho, G. D., Matasi, J., Tulshian, D., Coffin, V. L., and Carey, G. J. (2008) The anxiolytic-like effects of the novel, orally active nociception opioid receptor agonist SCH 221510 J. Pharmacol. Exp. Ther 326, 672-682
90. Waldischkin, K. A., Dysko, R. C., Collins, G. T., Ko, Y. A., Winger, G., and Ko, M. C. (2012) Phamacological characterization of NOP receptor agonists as abuse-free and constipation-free analgesics in monkeys FASEB J. 26, 1123.3
91. Weerts, E. M., Fantegrossi, W. E., and Goodwin, A. K. (2007) The value of nonhuman primates in drug abuse research Exp. Clin. Psychopharmacol. 15, 309-327
92. Podlesnik, C. A., Ko, M. C., Winger, G., Wichmann, J., Prinssen, E. P., and Woods, J. H. (2011) The effects of nociception/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkyes Psychopharmacology 213, 53-60
93. Lukas, S. E., Griffiths, R. R., and Brady, J. V. (1983) Buprenorphine self-administration by the baboon: comparison with other opioids NIDA Res. Monogr. 43, 178-183
94. Lutfy, K., Eitan, S., Bryant, C. D., Yang, Y. C., Saliminejad, N., and Walayn, W. 2003, Buprenorphine-induced antinociception is mediated by mu opioid receptors and compromised by concomitant activation of opioid receptor-like receptors J. Neurosci. 23, 10331-10337
95. Khroyan, T. V., Polgar, W. E., Jiang, F., Zaveri, N. T., and Toll, L. (2009) Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociception/orphanin FQ/mu opioid receptor agonists J. Pharmacol. Exp. Ther. 331, 946-953
96. Zaveri, N. T. (2011) The Nociceptin/Orphanin FQ Receptor (NOP) as a Target for Drug Abuse Medications Curr. Top. Med. Chem. 11, 1151-1156
97. Cami-Kobeci, G., Polgar, W. E., Khroyan, T. V., Toll, L., and Husbands, S. M. (2011) Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine J. Med. Chem. 54, 6531-6537
98. Khroyan, T. V, Polgar, W. E., Cami-Kobeci, G., Husbands, S. M., Zaveri, N. T., and Toll, L. (2011) The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6- methoxymorphinan-7-yl]-3,3-dimethyl-pentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward J. Pharmacol. Exp. Ther. 336, 952-961
99. Molinari, S., Camarda, V., Rizzi, A., Marzola, G., Salvadori, S., Marzola, E., Molinari, P., McDonald, J., Ko, M. C., Lambert, D. G., Calo', G., and Guerrini, R. (2012) [Dmt(1) ]N/OFQ(1-13)-NH(2), a potent nociceptin/orphanin FQ and opioid receptor universal agonist Br. J. Pharmacol. 10.1111/j.1476-5381. 2012.02115.x
100. Kimura, Y., Fujita, M., Hong, J., Lohith, T. G., Gladding, R. L., Zoghbi, S. S., Tauscher, J. A., Goebl, N., Rash, K. S., Chen, Z., Pedregal, C., Barth, V. N., Pike, V. W., and Innis, R. B. (2011) Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociception/orphanin FQ peptide receptors J. Nucl. Med. 52, 1638-1645
101. Lohith, T. G., Zoghbi, S. S., Morse, C. L., Araneta, M. F., Barth, V. N., Goebl, N. A., Tauscher, J. T., Pike, V. W., Innis, R. B., and Fujita, M. (2012) Brain and whole-body imaging of nociception/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A J. Nucl. Med. 53, 385-392
102. Thompson, A. A., Liu, W., Chun, E., Katritc, V., Wu, H., Vardy, E., Huang, X. P., Trapella, C., Guerrini, R., Calo, G., Roth, B. L., Cherezov, V., and Stevens, R. C. (2012) Structure of the nociception/orphanin FQ receptor in complex with a peptide mimetic Nature 485, 395-399
103. Daga, P. R. and Zaveri, N. T. (2012) Homology modeling and molecular dynamics simulations of the active state of the nociception receptor reveal new insights into agonist binding and activation Proteins 80, 1948-1961